Trial Profile
A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Delafloxacin (Primary) ; Aztreonam; Linezolid; Vancomycin
- Indications Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
- Focus Therapeutic Use
- Sponsors Melinta Therapeutics
- 17 Dec 2015 Results published in the Journal of Antimicrobial Chemotherapy
- 06 Sep 2012 Results were presented in a late-breaking abstract at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), according to a Rib-X Pharmaceuticals media release.
- 16 Dec 2011 Primary endpoint 'Clinical-cure-rate' has been met for delafloxacin versus vancomycin